.. Prise-en-charge-avant-chirurgie, 45 3.2.1. Biopsies, p.45

N. Etude-globale-des-groupes and C. , 61 6.1.1, p.64

E. Actuellement, . France, and . En-europe, plusieurs études cliniques sont en cours (PANACHE-01 et ESPAC-5) Ces études ont pour but d'évaluer de façon prospective et en intention de traiter, l'efficacité de différents traitements néoadjuvants chez les patients résécables d'emblée et borderline, p.90

J. Ferlay, E. Steliarova-foucher, J. Lortet-tieulent, S. Rosso, J. Coebergh et al., Reprint of: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, European Journal of Cancer, vol.51, issue.9, pp.1201-1203, 1990.
DOI : 10.1016/j.ejca.2015.05.004

M. Wagner, C. Redaelli, M. Lietz, C. Seiler, H. Friess et al., Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma, British Journal of Surgery, vol.91, issue.5
DOI : 10.1002/bjs.4484

R. Siegel, K. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin. 2015 Feb, vol.65, issue.1, pp.5-29, 2015.
DOI : 10.3322/caac.21208

H. Oettle, S. Post, and P. Neuhaus, Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer, JAMA, vol.297, issue.3, pp.267-77, 2007.
DOI : 10.1001/jama.297.3.267

J. Neoptolemos, D. Stocken, C. Bassi, P. Ghaneh, D. Cunningham et al., Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection, JAMA, vol.304, issue.10, pp.1073-81, 2010.
DOI : 10.1001/jama.2010.1275

J. Neoptolemos, J. Dunn, D. Stocken, J. Almond, K. Link et al., Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial, The Lancet, vol.358, issue.9293, pp.1576-85, 2001.
DOI : 10.1016/S0140-6736(01)06651-X

S. Gillen, T. Schuster, M. Zum-büschenfelde, C. Friess, H. et al., Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages, PLoS Medicine, vol.23, issue.4, 2010.
DOI : 10.1371/journal.pmed.1000267.s005

M. Assifi, X. Lu, G. Eibl, H. Reber, G. Li et al., Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials, Surgery, vol.150, issue.3, pp.466-73, 2011.
DOI : 10.1016/j.surg.2011.07.006

O. Turrini, F. Viret, L. Moureau-zabotto, J. Guiramand, V. Moutardier et al., Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma, European Journal of Surgical Oncology (EJSO), vol.35, issue.12, pp.1306-1317, 2009.
DOI : 10.1016/j.ejso.2009.06.005

URL : https://hal.archives-ouvertes.fr/hal-00556315

Q. Denost, C. Laurent, J. Adam, M. Capdepont, V. Vendrely et al., Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head, HPB, vol.15, issue.9, pp.716-739, 2013.
DOI : 10.1111/hpb.12039

C. Zhu, J. Shi, Y. Chen, W. Xie, and Y. Lin, Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: A meta-analysis, Radiotherapy and Oncology, vol.99, issue.2, pp.108-121, 2011.
DOI : 10.1016/j.radonc.2011.04.001

V. Moutardier, M. Giovannini, B. Lelong, G. Monges, V. Bardou et al., A phase II single institutional experience with preoperative radiochemotherapy in pancreatic adenocarcinoma, European Journal of Surgical Oncology (EJSO), vol.28, issue.5, 2002.
DOI : 10.1053/ejso.2002.1293

D. Palmer, D. Stocken, H. Hewitt, C. Markham, A. Hassan et al., A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin, Annals of Surgical Oncology, vol.223, issue.11, pp.2088-96, 2007.
DOI : 10.1245/s10434-007-9384-x

W. Regine, K. Winter, R. Abrams, H. Safran, J. Hoffman et al., Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma, JAMA, vol.299, issue.9, pp.1019-1045, 2008.
DOI : 10.1001/jama.299.9.1019

E. Simard, E. Ward, R. Siegel, and A. Jemal, Cancers with increasing incidence trends in the United States: 1999 through 2008, CA: A Cancer Journal for Clinicians, vol.37, issue.RR-16, pp.118-146, 2008.
DOI : 10.3322/caac.20141

R. Cress, D. Yin, L. Clarke, R. Bold, and E. Holly, Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control CCC, 2006.

J. Winter, J. Cameron, K. Campbell, M. Arnold, D. Chang et al., 1423 Pancreaticoduodenectomies for Pancreatic Cancer: A Single-Institution Experience???, Journal of Gastrointestinal Surgery, vol.10, issue.9, pp.1199-210, 2006.
DOI : 10.1016/j.gassur.2006.08.018

A. Duffy, M. Capanu, P. Allen, R. Kurtz, S. Olson et al., Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan

S. Teiblum, L. Thygesen, and C. Johansen, Sixty-One Years of Pancreatic Cancer in Denmark From 1943 to 2003, Pancreas, vol.38, issue.4, pp.374-382, 2009.
DOI : 10.1097/MPA.0b013e31819b71ae

I. Iarc, Monographs on the evaluation of carcinogenic risks to Humans Tobacco smoke and involuntary smoking, IARC, vol.83, 2004.

S. Iodice, S. Gandini, P. Maisonneuve, and A. Lowenfels, Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg Dtsch Ges Für Chir, pp.535-580, 2008.

D. Li, J. Morris, J. Liu, M. Hassan, R. Day et al., Body Mass Index and Risk, Age of Onset, and Survival in Patients With Pancreatic Cancer, JAMA, vol.301, issue.24, pp.2553-62, 2009.
DOI : 10.1001/jama.2009.886

R. Huxley, A. Ansary-moghaddam, A. Berrington-de-gonzález, F. Barzi, and M. Woodward, Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies, British Journal of Cancer, vol.95, issue.11, pp.2076-83, 2005.
DOI : 10.1093/jnci/89.18.1360

D. Li, S. Yeung, M. Hassan, M. Konopleva, and J. Abbruzzese, Antidiabetic Therapies Affect Risk of Pancreatic Cancer, Gastroenterology, vol.137, issue.2, pp.482-490, 2009.
DOI : 10.1053/j.gastro.2009.04.013

P. Maisonneuve, A. Lowenfels, H. Bueno-de-mesquita, P. Ghadirian, P. Baghurst et al., Past Medical History and Pancreatic Cancer Risk: Results From a Multicenter Case-Control Study, Annals of Epidemiology, vol.20, issue.2, pp.92-100, 2010.
DOI : 10.1016/j.annepidem.2009.11.010

URL : https://hal.archives-ouvertes.fr/hal-01260406

C. Shi, R. Hruban, and A. Klein, Familial pancreatic cancer, Arch Pathol Lab Med, vol.133, issue.3, pp.365-74, 2009.

D. Chu, W. Kohlmann, and D. Adler, Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes, JOP J Pancreas, vol.11, issue.3, pp.203-215, 2010.

R. Brand, M. Lerch, W. Rubinstein, J. Neoptolemos, D. Whitcomb et al., Advances in counselling and surveillance of patients at risk for pancreatic cancer, Gut, vol.56, issue.10, 2007.
DOI : 10.1136/gut.2006.108456

O. Turrini, C. Cano, A. Legoffic, J. Delpero, J. Dagorn et al., Genetic alterations in precancerous pancreatic lesions and their clinical implications, Gastroent??rologie Clinique et Biologique, vol.33, issue.10-11, pp.10-111028, 2009.
DOI : 10.1016/j.gcb.2009.08.007

J. Neoptolemos, D. Stocken, J. Dunn, J. Almond, H. Beger et al., Influence of Resection Margins on Survival for Patients With Pancreatic Cancer Treated by Adjuvant Chemoradiation and/or Chemotherapy in the ESPAC-1 Randomized Controlled Trial, Annals of Surgery, vol.234, issue.6, pp.758-68, 2001.
DOI : 10.1097/00000658-200112000-00007

F. Campbell, R. Smith, P. Whelan, R. Sutton, M. Raraty et al., Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1???mm of a resection margin, Histopathology, vol.27, issue.18 suppl (abstr, pp.277-83, 2009.
DOI : 10.1111/j.1365-2559.2009.03376.x

J. Lüttges, I. Vogel, M. Menke, D. Henne-bruns, B. Kremer et al., The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas, Virchows Archiv, vol.433, issue.3, pp.237-279, 1998.
DOI : 10.1007/s004280050242

J. Delpero, F. Paye, and P. Bachellier, Monographie de l'Association française de chirurgie. Cancer du pancréas, 2010.

C. Catalano, A. Laghi, F. Fraioli, F. Pediconi, A. Napoli et al., Pancreatic carcinoma: the role of high-resolution multislice spiral CT in the diagnosis and assessment of resectability, Eur Radiol, vol.13, issue.1, pp.149-56, 2003.

I. Francis, Pancreatic adenocarcinoma: diagnosis and staging using multidetector-row computed tomography (MDCT) and magnetic resonance imaging (MRI), Cancer Imaging, vol.7, issue.Special Issue A, 2007.
DOI : 10.1102/1470-7330.2007.9010

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727968

P. Legmann, O. Vignaux, B. Dousset, A. Baraza, L. Palazzo et al., Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography., American Journal of Roentgenology, vol.170, issue.5, pp.1315-1337, 1998.
DOI : 10.2214/ajr.170.5.9574609

W. Hartwig, L. Schneider, M. Diener, F. Bergmann, M. Büchler et al., Preoperative tissue diagnosis for tumours of the pancreas, British Journal of Surgery, vol.36, issue.1, pp.5-20, 2009.
DOI : 10.1002/bjs.6407

R. Bardales, E. Stelow, S. Mallery, R. Lai, and M. Stanley, Review of endoscopic ultrasound-guided fine-needle aspiration cytology, Diagnostic Cytopathology, vol.31, issue.2, pp.140-75, 2006.
DOI : 10.1002/dc.20300

P. Lévy, P. Hammel, and P. Ruszniewski, Diagnostic challenge in autoimmune pancreatitis: beware of shipwreck!, Gut, vol.57, issue.12, pp.1646-1653, 2008.
DOI : 10.1136/gut.2008.158972

S. Detlefsen, M. Drewes, A. Vyberg, M. Klöppel, and G. , Diagnosis of autoimmune pancreatitis by core needle biopsy: application of six microscopic criteria, Virchows Archiv, vol.15, issue.Suppl 1, 2009.
DOI : 10.1007/s00428-009-0747-5

M. Tempero, M. Malafa, S. Behrman, A. Benson, E. Casper et al., Pancreatic Adenocarcinoma, Version 2.2014, J Natl Compr Canc Netw, vol.12, issue.8, pp.1083-93, 2014.

|. Cancer-du-pancréas and . Snfge, org -Société savante médicale française d'hépatogastroentérologie et d'oncologie digestive [Internet], 2015.

E. Buc and A. Sauvanet, Duodénopancréatectomie céphalique. EMC -Tech Chir -Appar Dig, 2011.

J. Delpero, J. Boher, A. Sauvanet, L. Treut, Y. Sa-cunha et al., Pancreatic Adenocarcinoma with Venous Involvement: Is Up-Front Synchronous Portal-Superior Mesenteric Vein Resection Still Justified? A Survey of the Association Fran??aise de Chirurgie, Annals of Surgical Oncology, vol.19, issue.suppl 3, pp.1874-83
DOI : 10.1245/s10434-014-4304-3

O. Turrini, J. Ewald, L. Barbier, D. Mokart, J. Blache et al., Should the Portal Vein Be Routinely Resected During Pancreaticoduodenectomy For Adenocarcinoma?, Annals of Surgery, vol.257, issue.4, 2013.
DOI : 10.1097/SLA.0b013e318269d23c

A. Nakao, S. Takeda, S. Inoue, S. Nomoto, N. Kanazumi et al., Indications and Techniques of Extended Resection for Pancreatic Cancer, World Journal of Surgery, vol.28, issue.6, pp.976-82, 2006.
DOI : 10.1007/s00268-005-0438-6

H. Amano, F. Miura, N. Toyota, K. Wada, K. Katoh et al., Is pancreatectomy with arterial reconstruction a safe and useful procedure for locally advanced pancreatic cancer?, Journal of Hepato-Biliary-Pancreatic Surgery, vol.13, issue.6, pp.850-857, 2009.
DOI : 10.1007/s00534-009-0190-7

O. Ishikawa, H. Ohigashi, S. Imaoka, T. Teshima, T. Inoue et al., Concomitant Benefit of Preoperative Irradiation in Preventing Pancreas Fistula Formation After Pancreatoduodenectomy, Archives of Surgery, vol.126, issue.7, pp.885-894, 1960.
DOI : 10.1001/archsurg.1991.01410310095014

O. Turrini, V. Moutardier, J. Guiramand, B. Lelong, E. Bories et al., Hemorrhage after Duodenopancreatectomy: Impact of Neoadjuvant Radiochemotherapy and Experience with Sentinel Bleeding, World Journal of Surgery, vol.133, issue.2, pp.212-218, 2005.
DOI : 10.1007/s00268-004-7557-3

M. Winner, S. Goff, and J. Chabot, Neoadjuvant therapy for Non-metastatic Pancreatic Ductal Adenocarcinoma, Seminars in Oncology, vol.42, issue.1, pp.86-97
DOI : 10.1053/j.seminoncol.2014.12.008

C. Belli, S. Cereda, S. Anand, and M. Reni, Neoadjuvant therapy in resectable pancreatic cancer: A critical review, Cancer Treatment Reviews, vol.39, issue.5, pp.518-542, 2013.
DOI : 10.1016/j.ctrv.2012.09.008

O. Turrini, F. Viret, L. Moureau-zabotto, J. Guiramand, V. Moutardier et al., Neoadjuvant 5 Fluorouracil-Cisplatin Chemoradiation Effect on Survival in Patients with Resectable Pancreatic Head Adenocarcinoma: A Ten-Year Single Institution Experience, Oncology, vol.76, issue.6, pp.413-422, 2009.
DOI : 10.1159/000215928

J. Valle, D. Palmer, R. Jackson, T. Cox, J. Neoptolemos et al., Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study, Journal of Clinical Oncology, vol.32, issue.6, pp.504-516, 2014.
DOI : 10.1200/JCO.2013.50.7657

J. Mullen, J. Lee, H. Gomez, W. Ross, N. Fukami et al., Pancreaticoduodenectomy After Placement of Endobiliary Metal Stents, Journal of Gastrointestinal Surgery, vol.9, issue.8, pp.1094-104, 2005.
DOI : 10.1016/j.gassur.2005.08.006

F. Mornex, N. Girard, J. Scoazec, N. Bossard, M. Ychou et al., Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial, International Journal of Radiation Oncology*Biology*Physics, vol.65, issue.5, pp.1471-1479, 2006.
DOI : 10.1016/j.ijrobp.2006.02.054

URL : https://hal.archives-ouvertes.fr/hal-00428006

R. White, H. Hurwitz, M. Morse, C. Lee, M. Anscher et al., Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas, Annals of Surgical Oncology, vol.18, issue.10:, 2001.
DOI : 10.1007/s10434-001-0758-1

D. Evans, G. Varadhachary, C. Crane, C. Sun, J. Lee et al., Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head, Journal of Clinical Oncology, vol.26, issue.21, pp.3496-502, 2008.
DOI : 10.1200/JCO.2007.15.8634

S. Heinrich, M. Schäfer, A. Weber, T. Hany, U. Bhure et al., Neoadjuvant Chemotherapy Generates a Significant Tumor Response in Resectable Pancreatic Cancer Without Increasing Morbidity, Annals of Surgery, vol.248, issue.6, pp.1014-1036, 2008.
DOI : 10.1097/SLA.0b013e318190a6da

H. Golcher, T. Brunner, H. Witzigmann, L. Marti, W. Bechstein et al., Neoadjuvante Radiochemotherapie mit Gemcitabin/Cisplatin gefolgt von Resektion versus prim??rer Resektion bei resektablem Pankreaskopfkarzinom, Strahlentherapie und Onkologie, vol.189, issue.5, pp.7-16, 2015.
DOI : 10.1007/s00066-014-0737-7

C. Louvet, R. Labianca, P. Hammel, G. Lledo, M. Zampino et al., Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial, Journal of Clinical Oncology, vol.23, issue.15, pp.3509-3525, 2005.
DOI : 10.1200/JCO.2005.06.023

F. Leone, M. Gatti, P. Massucco, F. Colombi, E. Sperti et al., Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer, Cancer, vol.138, issue.2, pp.277-84, 2013.
DOI : 10.1002/cncr.27736

E. Kim, E. Ben-josef, J. Herman, T. Bekaii-saab, L. Dawson et al., A Multi- Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer. Cancer, pp.2692-700, 2013.

O. Turrini, M. Ychou, L. Moureau-zabotto, P. Rouanet, M. Giovannini et al., Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response, European Journal of Surgical Oncology (EJSO), vol.36, issue.10, pp.987-92, 2010.
DOI : 10.1016/j.ejso.2010.07.003

W. Sherman, K. Chu, J. Chabot, J. Allendorf, B. Schrope et al., Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma. Cancer, pp.673-80, 2015.

T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud et al., FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, New England Journal of Medicine, vol.364, issue.19, pp.1817-1842, 2011.
DOI : 10.1056/NEJMoa1011923

URL : https://hal.archives-ouvertes.fr/hal-00598658

M. Lee, S. Lee, S. Lee, Y. Lee, J. Hwang et al., 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy, Chemotherapy, vol.59, issue.4, pp.273-282, 2013.
DOI : 10.1159/000356158

K. Christians, S. Tsai, A. Mahmoud, R. P. Thomas, J. Wiebe et al., Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?, The Oncologist, vol.19, issue.3, pp.266-74, 2014.
DOI : 10.1634/theoncologist.2013-0273

L. Marthey, A. Sa-cunha, J. Blanc, M. Gauthier, A. Cueff et al., FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort, Annals of Surgical Oncology, vol.17, issue.11, pp.295-301
DOI : 10.1245/s10434-014-3898-9

J. Faris, L. Blaszkowsky, S. Mcdermott, A. Guimaraes, J. Szymonifka et al., FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience, The Oncologist, vol.18, issue.5, pp.543-551, 2013.
DOI : 10.1634/theoncologist.2012-0435

C. Cassinotto, A. Mouries, J. Lafourcade, E. Terrebonne, G. Belleannée et al., Locally Advanced Pancreatic Adenocarcinoma: Reassessment of Response with CT after Neoadjuvant Chemotherapy and Radiation Therapy, Radiology, vol.273, issue.1, pp.108-124, 2014.
DOI : 10.1148/radiol.14132914

D. Dindo, N. Demartines, and P. Clavien, Classification of Surgical Complications, Annals of Surgery, vol.240, issue.2, pp.205-218, 2004.
DOI : 10.1097/01.sla.0000133083.54934.ae

C. Bassi, C. Dervenis, G. Butturini, A. Fingerhut, C. Yeo et al., Postoperative pancreatic fistula: An international study group (ISGPF) definition, Surgery, vol.138, issue.1, pp.8-13, 2005.
DOI : 10.1016/j.surg.2005.05.001

K. Slankamenac, R. Graf, J. Barkun, M. Puhan, and P. Clavien, The Comprehensive Complication Index, Annals of Surgery, vol.258, issue.1, p.2013
DOI : 10.1097/SLA.0b013e318296c732

T. André, Cancer du pancréas [Internet]. Thésaurus national de cancérologie digestive, 2015.

M. Eloubeidi, A. Tamhane, S. Varadarajulu, and C. Wilcox, Frequency of major complications after EUS-guided FNA of solid pancreatic masses: a prospective evaluation, Gastrointestinal Endoscopy, vol.63, issue.4, pp.622-631, 2006.
DOI : 10.1016/j.gie.2005.05.024

F. Gress, H. Michael, D. Gelrud, P. Patel, K. Gottlieb et al., EUS-guided fine-needle aspiration of the pancreas: Evaluation of pancreatitis as a complication, Gastrointestinal Endoscopy, vol.56, issue.6, pp.864-871, 2002.
DOI : 10.1016/S0016-5107(02)70361-1

O. Toole, D. Palazzo, L. Arotçarena, R. Dancour, A. Aubert et al., Assessment of complications of EUS-guided fine-needle aspiration, Gastrointestinal Endoscopy, vol.53, issue.4, pp.470-474, 2001.
DOI : 10.1067/mge.2001.112839

N. Van-der-gaag, E. Rauws, C. Van-eijck, M. Bruno, E. Van-der-harst et al., Preoperative Biliary Drainage for Cancer of the Head of the Pancreas, New England Journal of Medicine, vol.362, issue.2, pp.129-166, 2010.
DOI : 10.1056/NEJMoa0903230

Y. Fang, K. Gurusamy, Q. Wang, B. Davidson, H. Lin et al., Pre-operative biliary drainage for obstructive jaundice, Cochrane Database Syst Rev, vol.336, issue.3, p.5444, 2012.
DOI : 10.1002/14651858.CD005444.pub3

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164472

C. Ferrone, G. Marchegiani, T. Hong, D. Ryan, V. Deshpande et al., Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer, Annals of Surgery, vol.261, issue.1, pp.12-19, 2015.
DOI : 10.1097/SLA.0000000000000867

C. Xu, X. Xue, N. Liang, D. Xu, F. Liu et al., Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis, Journal of Cancer Research and Clinical Oncology, vol.225, issue.4, pp.549-59
DOI : 10.1007/s00432-013-1572-4

A. Morganti, M. Massaccesi, L. Torre, G. Caravatta, L. Piscopo et al., A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer, Annals of Surgical Oncology, vol.240, issue.Suppl 3, pp.194-205, 2010.
DOI : 10.1245/s10434-009-0762-4

C. Yeo, R. Abrams, L. Grochow, T. Sohn, S. Ord et al., Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Postoperative Adjuvant Chemoradiation Improves Survival, Annals of Surgery, vol.225, issue.5, 1997.
DOI : 10.1097/00000658-199705000-00018

J. Klinkenbijl, J. Jeekel, T. Sahmoud, R. Van-pel, M. Couvreur et al., Adjuvant Radiotherapy and 5-Fluorouracil After Curative Resection of Cancer of the Pancreas and Periampullary Region, Annals of Surgery, vol.230, issue.6, p.776, 1999.
DOI : 10.1097/00000658-199912000-00006

R. Scodan, F. Mornex, N. Girard, C. Mercier, P. Valette et al., Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review, Annals of Oncology, vol.20, issue.8
DOI : 10.1093/annonc/mdp015

O. Turrini, V. Moutardier, J. Guiramand, F. Viret, M. Giovaninni et al., Long term morbidity of neoadjuvant chemoradiation for pancreatic head adenocarcinoma, European Journal of Surgical Oncology (EJSO), vol.32, issue.1, pp.77-86, 2006.
DOI : 10.1016/j.ejso.2005.10.004

P. Addeo, E. Rosso, P. Fuchshuber, E. Oussoultzoglou, D. Blasi et al., Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy. Oncology, 2015.

P. Internet and ]. , Available from, 2015.